Clinical Trial

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The DEPECA-1 trial is the first systematic Phase II trial to evaluate response and survival to a combination of antibody-drug conjugate enfortumab vedotin plus the PD-L1 inhibitor avelumab in patients with locally advanced and metastatic penile squamous cell carcinoma (PeCa) in the 1st line setting.
Protocol Amendment History 1 change
notable Trial sites expanded: 2 -> 7 locations 2026-04-17
Trial Details
NCT Number NCT07110038
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Merck KGaA, Darmstadt, Germany, Astellas Pharma GmbH, University Hospital Tübingen
Conditions Penile Squamous Cell Carcinoma (PSCC)
Enrollment 25 participants
Start Date 2025-12-16
Primary Completion 2029-05 (estimated)
Study Completion 2030-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-22